摘要
帕金森病(PD)的药理学治疗仅限于多巴胺的兴奋剂和抗胆碱药,但这两种并不能阻止疾病的发生,在1967年,左旋多巴被引入治疗,目前这种药依然是最好和最常用的,因为它对病人的生活质量产生了一个真正的改善。但是左旋多巴的缺点是会带来一些运动障碍的严重副作用。对帕金森病治疗的新药研究还仅限于可以降低副作用治疗的化合物,例如左旋多巴诱导的运动障碍,制药公司并没有新药发明来阻止疾病的一个可能解释是,因为引起黑质纹状体系统多巴胺能神经元含有黑色素损失的机制仍然是未知的,与家族性PD有关的基因的发现(α-突触核蛋白,帕金,pink-1,DJ- 1,LRRK2 GBA1,等)造成了一个巨大的基础投入研究,以了解这些蛋白质在疾病中的作用。人们普遍认为多巴胺能神经元含有黑色素的损失涉及线粒体功能障碍,蛋白质代谢障碍,α-突触核蛋白的神经毒性低聚物的聚合、氧化的炎症反应及内质网应激所诱导,但这些机制的问题仍然没有答案。氨基铬,多巴胺的氧化和黑色素的前体产品,直接参与机制五和六可能是一个更好的PD的临床前模型
关键词: 多巴胺,药物代谢,醌,氨基铬,M2-2谷胱甘肽转移酶,心肌黄酶,帕金森病,神经退行性疾病
Current Medicinal Chemistry
Title:Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
Volume: 23 Issue: 4
Author(s): Juan Segura-Aguilar, Patricia Muñoz and Irmgard Paris
Affiliation:
关键词: 多巴胺,药物代谢,醌,氨基铬,M2-2谷胱甘肽转移酶,心肌黄酶,帕金森病,神经退行性疾病
摘要: The pharmacological treatment of Parkinson´s disease (PD) is limited to dopamine agonists and anti-cholinergic drugs that do not stop the progress of disease. LDopa was introduced to the treatment in 1967; this drug is still the best and most commonly used drug since it generates a real improvement in patient quality of life, but the disadvantage of L-dopa is that this positive effect is followed by severe side effects such as dyskinesia. The search for a new drug in the treatment of PD is limited to compounds which decrease the side effects of the drugs used in the treatment of the disease, such as L-dopa-induced dyskinesia. One possible explanation for pharmaceutical companies not developing new drugs to stop disease development is because the mechanism which induces the loss of dopaminergic neurons containing neuromelanin of the nigrostriatal system is still unknown. The discovery of genes (alpha-synuclein, parkin, pink-1, DJ- 1, LRRK2, GBA1, etc.) associated with familial forms of PD resulted in an enormous input into basic research in order to understand the role of these proteins in the disease. It is generally accepted that the loss of dopaminergic neurons containing neuromelanin involves mitochondrial dysfunction, protein degradation dysfunction, the aggregation of alpha-synuclein to neurotoxic oligomers, oxidative neuroinflammation and endoplasmic reticulum stress, but the question of what induces these mechanisms remains unanswered. Aminochrome, the product of dopamine oxidation and the precursor of neuromelanin, is directly involved in five of the six mechanisms and may be a better PD preclinical model.
Export Options
About this article
Cite this article as:
Juan Segura-Aguilar, Patricia Muñoz and Irmgard Paris , Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease, Current Medicinal Chemistry 2016; 23 (4) . https://dx.doi.org/10.2174/0929867323666151223094103
DOI https://dx.doi.org/10.2174/0929867323666151223094103 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Current Drug Targets Platelet-Activating Factor (PAF) Antagonists Attenuate Inflammatory- Based Pain: Potential Cellular and Anatomical Sites of PAF Action
Central Nervous System Agents in Medicinal Chemistry β-Synuclein Assembly as a Therapeutic Target of Parkinsons Disease and Related Disorders
Current Pharmaceutical Design Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties
Current Alzheimer Research PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS
Current Pharmaceutical Design Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics Use of Human Umbilical Cord Blood (HUCB) Cells to Repair the Damaged Brain
Current Neurovascular Research Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery
Current Neuropharmacology Experimental Brain Ischemic Preconditioning: A Concept to Putative Targets
CNS & Neurological Disorders - Drug Targets Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Interaction of Proteins with Lipid Rafts Through Glycolipid-Binding Domains:Biochemical Background and Potential Therapeutic Applications
Current Medicinal Chemistry Recent Multi-target Approaches on the Development of Anti- Alzheimer's Agents Integrating Metal Chelation Activity
Current Medicinal Chemistry MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy